Professional Documents
Culture Documents
Poisoning & Drug Overdose 7th Edition Kent R. Olson (Ed.) full chapter instant download
Poisoning & Drug Overdose 7th Edition Kent R. Olson (Ed.) full chapter instant download
https://ebookmass.com/product/drug-compounding-for-veterinary-
professionals-lauren-r-eichstadt-forsythe/
https://ebookmass.com/product/group-dynamics-7th-edition-
donelson-r-forsyth/
https://ebookmass.com/product/populism-and-trade-kent-jones-kent-
jones/
https://ebookmass.com/product/elsevier-weekblad-
week-26-2022-gebruiker/
Biochemistry, 7th ed: The Molecular basis of life 7th
Edition James R. Mckee
https://ebookmass.com/product/biochemistry-7th-ed-the-molecular-
basis-of-life-7th-edition-james-r-mckee/
https://ebookmass.com/product/ryans-retina-7th-edition-srinivas-
r-sadda-md-editor/
https://ebookmass.com/product/ebook-pdf-management-7th-asia-
pacific-edition-by-john-r-schermerhorn/
https://ebookmass.com/product/ise-an-introduction-to-business-
ethics-7th-edition-joseph-r-desjardins/
https://ebookmass.com/product/entrepreneur-to-millionaire-kent-
billingsley/
Comprehensive Evaluation and Treatment: Provides a step-wise
Emergency
Treatment
approach to the evaluation and treatment of coma, seizures, shock,
and other common complications of poisoning and to the proper use of
gastric decontamination and dialysis procedures.
Common Poisons
Specific Poisons and Drugs: Diagnosis and Treatment: Alphabeti-
& Drugs
cal listing of specific drugs and poisons, including the pathophysiology,
toxic dose and level, clinical presentation, diagnosis, and specific treat-
ment associated with each substance.
Therapy
and antidotes discussed in the two preceding sections, including their
pharmacology, indications, adverse effects, drug interactions, recom-
mended dosage, and formulations.
POISONING
& DRUG
OVERDOSE
Edited by
Kent R. Olson, MD, FACEP, FACMT, FAACT
Clinical Professor of Medicine and Pharmacy,
University of California, San Francisco;
Co-Medical Director, California Poison Control System,
San Francisco Division (retired)
Associate Editors
New York Chicago San Francisco Lisbon London Madrid Mexico City
Milan New Delhi San Juan Seoul Singapore Sydney Toronto
ISBN: 978-0-07-183980-8
MHID: 0-07-183980-1
The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-183979-2,
MHID: 0-07-183979-8.
All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after
every occurrence of a trademarked name, we use names in an editorial fashion only, and to the benefit
of the trademark owner, with no intention of infringement of the trademark. Where such designations
appear in this book, they have been printed with initial caps.
McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and
sales promotions or for use in corporate training programs. To contact a representative, please visit the
Contact Us page at www.mhprofessional.com.
Notice
Medicine is an ever-changing science. As new research and clinical experience broaden our knowl-
edge, changes in treatment and drug therapy are required. The authors and the publisher of this work
have checked with sources believed to be reliable in their efforts to provide information that is com-
plete and generally in accord with the standards accepted at the time of publication. However, in view
of the possibility of human error or changes in medical sciences, neither the authors nor the publisher
nor any other party who has been involved in the preparation or publication of this work warrants that
the information contained herein is in every respect accurate or complete, and they disclaim all respon-
sibility for any errors or omissions or for the results obtained from use of the information contained
in this work. Readers are encouraged to confirm the information contained herein with other sources.
For example and in particular, readers are advised to check the product information sheet included in
the package of each drug they plan to administer to be certain that the information contained in this
work is accurate and that changes have not been made in the recommended dose or in the contraindica-
tions for administration. This recommendation is of particular importance in connection with new or
infrequently used drugs.
TERMS OF USE
This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the
work. Use of this work is subject to these terms. Except as permitted under the Copyright Act of 1976
and the right to store and retrieve one copy of the work, you may not decompile, disassemble, reverse
engineer, reproduce, modify, create derivative works based upon, transmit, distribute, disseminate,
sell, publish or sublicense the work or any part of it without McGraw-Hill Education’s prior consent.
You may use the work for your own noncommercial and personal use; any other use of the work is
strictly prohibited. Your right to use the work may be terminated if you fail to comply with these terms.
THE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND ITS LICENSORS
MAKE NO GUARANTEES OR WARRANTIES AS TO THE ACCURACY, ADEQUACY OR COM-
PLETENESS OF OR RESULTS TO BE OBTAINED FROM USING THE WORK, INCLUDING
ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK
OR OTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its licensors do not warrant
or guarantee that the functions contained in the work will meet your requirements or that its operation
will be uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable to
you or anyone else for any inaccuracy, error or omission, regardless of cause, in the work or for any
damages resulting therefrom. McGraw-Hill Education has no responsibility for the content of any
information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or
its licensors be liable for any indirect, incidental, special, punitive, consequential or similar damages
that result from the use of or inability to use the work, even if any of them has been advised of the
possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever
whether such claim or cause arises in contract, tort or otherwise.
Contents
Authors ..................................................................................................................... vi
Preface ..................................................................................................................... xii
Index....................................................................................................................... 783
The index includes generic drug and chemical names.
Ann Arens, MD
Medical Toxicology Fellow, Department of Medicine, University of California,
San Francisco, California; Medical Toxicologist, Minnesota Poison Control System;
Assistant Professor, Department of Emergency Medicine, University of Minnesota
Patil Armenian, MD
Associate Professor, Assistant Research Director, Department of Emergency
Medicine, University of California, San Francisco-Fresno
John R. Balmes, MD
Professor of Medicine, University of California, San Francisco; Division of Environmental
Health Sciences, School of Public Health, University of California, Berkeley
Neal L. Benowitz, MD
Professor of Medicine and Chief, Division of Clinical Pharmacology, Medicine and
Bioengineering & Therapeutic Sciences, Zuckerberg San Francisco General Hospital/
University of California, San Francisco
Richard F. Clark, MD
Medical Director, San Diego Division, California Poison Control System;
Director, Division of Medical Toxicology, University of California, San Diego Medical Center
vi
Jonathan B. Ford, MD
Assistant Professor, Emergency Medicine, University of California, Davis
Kai Li, MD
Medical Toxicology Fellow, Department of Emergency Medicine, University of California,
San Francisco
Alicia B. Minns, MD
Assistant Clinical Professor of Emergency Medicine, Department of Emergency Medicine,
University of California, San Diego
Eileen Morentz
Poison Information Provider, California Poison Control System, San Francisco Division
Charles W. O’Connell, MD
Clinical Professor of Emergency Medicine, Division of Medical Toxicology, University of
California, San Diego
Steven R. Offerman, MD
Assistant Professor, Department of Emergency Medicine, University of California, Davis;
Division of Emergency Medicine, Kaiser Permanente, South Sacramento Medical Center,
Sacramento, California
Joshua B. Radke
Medical Toxicology Fellow, Department of Emergency Medicine, University of California,
Davis
Cyrus Rangan, MD
Assistant Medical Director, California Poison Control System; Director, Toxics
Epidemiology Program, Los Angeles County Department of Health Services; Attending
Staff, Children’s Hospital, Los Angeles, California
Daniel J. Repplinger, MD
Assistant Clinical Professor, Department of Emergency Medicine, University of California,
San Francisco; Zuckerberg San Francisco General Hospital, San Francisco, California
Aaron Schneir, MD
Professor of Emergency Medicine, Division of Medical Toxicology, Department of
Emergency Medicine, University of California, San Diego
Craig Smollin, MD
Medical Director, California Poison Control System, San Francisco Division; Associate
Professor of Emergency Medicine, University of California, San Francisco
Jeffrey R. Suchard, MD
Professor of Clinical Emergency Medicine and Pharmacology, Department of Emergency
Medicine, University of California, Irvine
Mark E. Sutter, MD
Associate Professor of Emergency Medicine, University of California, Davis
Janna H. Villano, MD
Clinical Faculty, Emergency Medicine, University of California, San Diego
Kathy Vo, MD
Medical Toxicology Fellow, California Poison Control System, San Francisco Division,
University of California, San Francisco; Assistant Clinical Professor of Emergency
Medicine, University of California, San Francisco
Rais Vohra, MD
Assistant Professor of Emergency Medicine, University of California,
San Francisco-Fresno
Poisoning & Drug Overdose provides practical advice for the diagnosis and man-
agement of poisoning and drug overdose and concise information about common
industrial chemicals.
The manual is divided into four sections and an index, each identified by a black tab
in the right margin. Section I leads the reader through initial emergency management,
including treatment of coma, hypotension, and other common complications; physical
and laboratory diagnosis; and methods of decontamination and enhanced elimination
of poisons. Section II provides detailed information for approximately 150 common
drugs and poisons. Section III describes the use and side effects of approximately 60
antidotes and therapeutic drugs. Section IV describes the medical management of
chemical spills and occupational chemical exposures and includes a table of over 500
chemicals. The Index is comprehensive and extensively cross-referenced.
The manual is designed to allow the reader to move quickly from section to section,
obtaining the needed information from each. For example, in managing a patient with
isoniazid intoxication, the reader will find specific information about isoniazid toxicity
in Section II, practical advice for gut decontamination and management of complica-
tions such as seizures in Section I, and detailed information about dosing and side
effects for the antidote pyridoxine in Section III.
ACKNOWLEDGMENTS
The success of the first and second editions of this manual would not have been pos-
sible without the combined efforts of the staff, faculty, and fellows of the San Francisco
Bay Area Regional Poison Control Center, to whom I am deeply indebted. From its
inception, this book has been a project by and for our poison center; as a result, all
royalties from its sale have gone to our center’s operating fund and not to any indi-
vidual editor or author.
In January 1997, four independent poison control centers joined their talents to
become the California Poison Control System, administered by the University of
California, San Francisco. With the third, fourth, fifth, and sixth editions, the manual
became a project of our statewide system, bringing in new authors and editors.
On behalf of the authors and editors of the seventh edition, my sincere thanks go
to all those who contributed to one or more of the first six editions:
xii
We are also grateful for the numerous comments and suggestions received from col-
leagues, students, and the editorial staff at McGraw-Hill, which helped us to improve
the manual with each edition.
Kent R. Olson, MD
San Francisco, California
September 2017
AIRWAY
I. Assessment. The most common factor contributing to death from drug overdose
or poisoning is loss of airway-protective reflexes with subsequent airway obstruc-
tion caused by the flaccid tongue, pulmonary aspiration of gastric contents, or
respiratory arrest. All poisoned patients should be suspected of having a poten-
tially compromised airway.
A. Patients who are awake and talking are likely to have intact airway reflexes
but should be monitored closely because worsening intoxication can result in
rapid loss of airway control.
B. In a lethargic or obtunded patient, the response to stimulation of the naso-
pharynx (eg, does the patient react to placement of a nasal airway?) or the
presence of a spontaneous cough reflex may provide an indirect indication
of the patient’s ability to protect the airway. If there is any doubt, it is best to
perform endotracheal intubation (see below).
II. Treatment. Optimize the airway position and perform endotracheal intubation if
necessary. Early use of naloxone (p 584) or flumazenil (p 556) may awaken a
patient intoxicated with opioids or benzodiazepines, respectively, and obviate the
need for endotracheal intubation. (Note: Flumazenil is not recommended except
in very select circumstances, as its use may precipitate seizures.)
A. Position the patient and clear the airway.
1. Optimize the airway position to force the flaccid tongue forward and maxi-
mize the airway opening. The following techniques are useful. Caution: Do
not perform neck manipulation if you suspect a neck injury.
a. Place the neck and head in the “sniffing” position, with the neck flexed
forward and the head extended.
b. Apply the “jaw thrust” maneuver to create forward movement of the
tongue without flexing or extending the neck. Pull the jaw forward by
placing the fingers of each hand on the angle of the mandible just below
the ears. (This motion also causes a painful stimulus to the angle of the
jaw, the response to which reflects the patient’s depth of coma.)
c. Place the patient in a head-down, left-sided position that allows the
tongue to fall forward and secretions or vomitus to drain out of the mouth.
AIRWAY (p 1)
BREATHING (p 5)
Ventilatory failure? (p 5)
Obtain arterial blood gases
Assist with bag/mask device
Give supplemental oxygen Hypoxia? (p 6)
Bronchospasm? (p 8)
CIRCULATION (p 8)
Bradycardia/AV block? (p 9)
Measure blood pressure/pulse
Monitor electrocardiogram
Start 1–2 IV lines Prolonged QRS interval? (p 10)
Obtain routine bloodwork
Tachycardia? (p 12)
Hypotension? (p 15)
Seizures? (p 23)
Agitation? (p 24)
DECONTAMINATION (p 50)
Hemodialysis
Continuous renal replacement
therapy
Repeat-dose charcoal
DISPOSITION (p 60)
Regional poison center
Toxicology consultation consultation [(800)222-1222]
Psychosocial evaluation
A B
FIGURE I–2. Two routes for endotracheal intubation. A: Nasotracheal intubation. B: Orotracheal intubation.
2. If the airway is still not patent, examine the oropharynx and remove any
obstruction or secretions by suction, by a sweep with the finger, or with
Magill forceps.
3. The airway can also be maintained with artificial oropharyngeal or naso-
pharyngeal airway devices. These devices are placed in the mouth or
nose to lift the tongue and push it forward. They are only temporary mea-
sures. A patient who can tolerate an artificial airway without complaint prob-
ably needs an endotracheal tube.
B. Perform endotracheal intubation if personnel trained in the procedure are
available. Intubation of the trachea provides the most reliable protection of the
airway, preventing obstruction and reducing the risk for pulmonary aspiration
of gastric contents as well as allowing mechanically assisted ventilation. How-
ever, it is not a simple procedure and should be attempted only by those with
training and experience. Complications include vomiting with pulmonary aspi-
ration; local trauma to the oropharynx, nasopharynx, and larynx; inadvertent
intubation of the esophagus or a mainstem bronchus; worsening acidosis due
to apnea; and failure to intubate the patient after respiratory arrest has been
induced by a neuromuscular blocker. There are two routes for endotracheal
intubation: nasotracheal and orotracheal.
1. Nasotracheal intubation. In nasotracheal intubation, a soft, flexible tube is
passed through the nose and into the trachea by using a “blind” technique
(Figure I–2A).
a. Advantages
(1) It may be performed in a conscious or semiconscious patient without
the need for neuromuscular paralysis.
(2) Once placed, it is usually better tolerated than an orotracheal tube.
b. Disadvantages
(1) Perforation of the nasal mucosa with epistaxis.
(2) Stimulation of vomiting in an obtunded patient.
(3) Patient must be breathing spontaneously.
(4) Anatomically more difficult in infants because of their anterior epiglottis.
2. Orotracheal intubation. In orotracheal intubation, the tube is passed
through the patient’s mouth into the trachea under direct vision (Figure I–2B),
with the aid of a video laryngoscope device, or with the aid of a long, flexible
stylet (bougie).
a. Technique
b. Advantages
(1) Performed under direct or video-assisted visualization, making acciden-
tal esophageal intubation less likely than with nasotracheal intubation.
(2) Insignificant risk for bleeding.
(3) Patient need not be breathing spontaneously.
(4) Higher success rate than that achieved via the nasotracheal route.
c. Disadvantages
(1) Frequently requires neuromuscular paralysis, creating a risk for respi-
ratory acidosis, or fatal respiratory arrest if intubation is unsuccessful.
(2) Requires neck manipulation, which may cause spinal cord injury if
the patient has also had neck trauma.
3. Cricothyrotomy or tracheotomy may be necessary in the rare patient whose
larynx is damaged or distorted making endotracheal intubation through the
pharynx impossible.
C. Extraglottic airway devices. The role of newer advanced airway equipment,
such as the laryngeal mask airway (LMA), in patients with poisoning or drug
overdose is not known; although these devices are easier to insert than endo-
tracheal tubes, especially in some patients with “difficult” airways, they do
not provide adequate protection against pulmonary aspiration of gastric con-
tents, and they cannot be used in patients with laryngeal edema, injury, or
laryngospasm.
BREATHING
Along with airway problems, breathing difficulties are the major cause of morbidity and
death in patients with poisoning or drug overdose. Patients may have one or more of
the following complications: ventilatory failure, hypoxia, and bronchospasm.
I. Ventilatory failure
A. Assessment. Normal ventilation, or gas exchange, requires a number of
interdependent physiological processes. Ventilatory failure can have multiple
causes, including failure of the ventilatory muscles, central depression of
respiratory drive, and severe pneumonia or pulmonary edema. Examples of
drugs and toxins that cause ventilatory failure, and the causative mechanisms,
are listed in Table I–1.
B. Complications. Ventilatory failure is the most common cause of death in poi-
soned patients.
1. Hypoxia may result in brain damage, cardiac dysrhythmias, and cardiac arrest.
2. Hypercarbia results in acidosis, which may contribute to worsening sys-
temic toxicity and dysrhythmias, especially in patients with salicylate toxicity
or tricyclic antidepressant overdoses.
C. Differential diagnosis. Rule out the following:
1. Bacterial or viral pneumonia.
2. Viral encephalitis or myelitis (eg, polio).
3. Traumatic or ischemic spinal cord or central nervous system (CNS) injury.
4. Tetanus, causing rigidity of chest wall muscles.
5. Pneumothorax.